SUPN News and Press, Supernus Pharmaceuticals Inc.

2024-07-02 07:30:00 ET Summary Supernus' revenue growth is hindered by rapidly declining Trokendi sales. There are no pipeline products reliably poised to help out with revenues. Qelbree provides the one bright point on Supernus' revenues. This is my eighth Supernus ( ...

ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...

2024-05-24 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharm...

2024-05-17 15:00:04 ET More on the markets SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards SPY: Get Ready For A Recessionary Bear Market DWS is cautiously optimistic about stocks, but expects 'jittery' market Investors pur...

ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and confe...

2024-05-08 20:28:08 ET Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Conference Call May 08, 2024 04:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer ...

2024-05-08 16:56:17 ET More on Supernus Pharmaceuticals Supernus Pharmaceuticals: Moving Through An 'Inflection Year' Supernus stock slides as FDA rejects Parkinson's disease infusion device Seeking Alpha’s Quant Rating on Supernus Pharmaceuticals Hist...

Net sales of Qelbree ® increased 75% to $45.1 million compared to first quarter 2023. Total revenues were $143.6 million. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non-GAAP) (1) increased 12% to $100.7 million compared to first ...

2024-05-07 17:20:52 ET More on Supernus Pharmaceuticals Supernus Pharmaceuticals: Moving Through An 'Inflection Year' Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript Supernus stock slides as FDA rejects Parkinson's disease infusion device ...